SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.
Identifieur interne : 000675 ( Main/Exploration ); précédent : 000674; suivant : 000676SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.
Auteurs : Jean-Michel Pawlotsky [France]Source :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2020.
Abstract
December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection.
DOI: 10.1093/cid/ciaa587
PubMed: 32409832
PubMed Central: PMC7239253
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.</title><author><name sortKey="Pawlotsky, Jean Michel" sort="Pawlotsky, Jean Michel" uniqKey="Pawlotsky J" first="Jean-Michel" last="Pawlotsky">Jean-Michel Pawlotsky</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM U955, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U955, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32409832</idno><idno type="pmid">32409832</idno><idno type="doi">10.1093/cid/ciaa587</idno><idno type="pmc">PMC7239253</idno><idno type="wicri:Area/Main/Corpus">001291</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001291</idno><idno type="wicri:Area/Main/Curation">001291</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001291</idno><idno type="wicri:Area/Main/Exploration">001291</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.</title><author><name sortKey="Pawlotsky, Jean Michel" sort="Pawlotsky, Jean Michel" uniqKey="Pawlotsky J" first="Jean-Michel" last="Pawlotsky">Jean-Michel Pawlotsky</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>INSERM U955, Créteil, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U955, Créteil</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32409832</PMID><DateRevised><Year>2020</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciaa587</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciaa587</ELocationID><Abstract><AbstractText>December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called COVID-19, caused by a newly identified coronavirus, SARS-CoV-2. No therapeutic option is available to treat this infection that has already killed more than 235,000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a non-immunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached Phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the lifecycle of many coronaviruses, including SARS-CoV and MERS-CoV, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at-risk of severe forms of SARS-CoV-2 infection.</AbstractText><CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pawlotsky</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U955, Créteil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32409832</ArticleId><ArticleId IdType="pii">5837360</ArticleId><ArticleId IdType="doi">10.1093/cid/ciaa587</ArticleId><ArticleId IdType="pmc">PMC7239253</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Créteil</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Pawlotsky, Jean Michel" sort="Pawlotsky, Jean Michel" uniqKey="Pawlotsky J" first="Jean-Michel" last="Pawlotsky">Jean-Michel Pawlotsky</name></region><name sortKey="Pawlotsky, Jean Michel" sort="Pawlotsky, Jean Michel" uniqKey="Pawlotsky J" first="Jean-Michel" last="Pawlotsky">Jean-Michel Pawlotsky</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000675 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000675 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32409832
|texte= SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32409832" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |